Search results
Results From The WOW.Com Content Network
On Monday, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) released topline results from the Phase 3 PALISADE study of plozasiran in patients with genetically confirmed or clinically diagnosed ...
For premium support please call: 800-290-4726 more ways to reach us
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference (RNAi) mechanisms of action. [2] [3] The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular ...
For premium support please call: 800-290-4726 more ways to reach us
Miller was vice president of intellectual property at a public pharmaceutical company, Arrowhead Pharmaceuticals, from 2004 to 2010. [3] He co-authored a book called The Handbook of Nanotechnology: Business, Policy, and Intellectual Property Law. [3] [2] Miller founded Pasadena based technology company CaliGroup.
ARO-HSD, also known as GSK4532990, is a small interfering RNA developed for the treatment of fatty liver disease.Based on the observation that "loss-of-function HSD17β13 mutations protect against the development of chronic liver disease," the therapeutic attempts to induce this loss of function and thus improve liver disease.
A study confirmed that side effects like pancreatitis and kidney damage are possible while taking GLP-1s like Ozempic. Here's what a doctor wants you to know.
Arrowhead Research is using technology from Alnylam and Isis to create gene interfering drugs targeting kidney disease and cancer. Two of the largest drugmakers, Roche and Shire , found Arrowhead ...